The iPhone maker's shares [rallied for a second day]( ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.

Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...

US stocks trimmed losses on Thursday, finishing mixed after President Trump's sweeping tariffs hit dozens of US trade ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, while Nasdaq ended slightly higher. Shares of cybersecurity firm Fortinet ...

US stocks trimmed losses on Thursday as President Trump's sweeping tariffs hit dozens of US trade partners after his self-imposed deadline for countries to strike deals expired. Meanwhile, Trump also ...

Stocks were falling Thursday after President Donald Trump’s sweeping tariffs went into effect and initial jobless claims came in higher than expected.These stocks were moving:Eli Lilly slumped 14% ...

U.S. stocks are drifting lower after President Donald Trump’s latest tariffs took effect on dozens of countries, but the moves are modest and stocks rose in much of the rest ...